Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Hypofractionated radiotherapy in prostate cancer].
Supiot S, Créhange G, Latorzeff I, Pommier P, Paumier A, Rio E, Delaroche G, Guérif S, Catton C, Martin J, Lisbona A. Supiot S, et al. Among authors: guerif s. Cancer Radiother. 2013 Oct;17(5-6):349-54. doi: 10.1016/j.canrad.2013.05.005. Epub 2013 Aug 20. Cancer Radiother. 2013. PMID: 23973460 Review. French.
[Postoperative radiotherapy of prostate cancer].
Guérif S, Latorzeff I, Lagrange JL, Hennequin C, Supiot S, Garcia A, François P, Soulié M, Richaud P, Salomon L. Guérif S, et al. Cancer Radiother. 2014 Oct;18(5-6):517-23. doi: 10.1016/j.canrad.2014.07.149. Epub 2014 Sep 5. Cancer Radiother. 2014. PMID: 25195116 Review. French.
[Prostate cancer brachytherapy].
Pommier P, Guérif S, Peiffert D, Créhange G, Hannoun-Lévi JM, de Crevoisier R. Pommier P, et al. Among authors: guerif s. Cancer Radiother. 2016 Sep;20 Suppl:S210-5. doi: 10.1016/j.canrad.2016.07.038. Epub 2016 Aug 11. Cancer Radiother. 2016. PMID: 27523412 French.
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).
Sargos P, Guerif S, Latorzeff I, Hennequin C, Pommier P, Lagrange JL, Créhange G, Chapet O, de Crevoisier R, Azria D, Supiot S, Habibian M, Soulié M, Richaud P. Sargos P, et al. Among authors: guerif s. Cancer Treat Rev. 2015 Dec;41(10):814-20. doi: 10.1016/j.ctrv.2015.10.005. Epub 2015 Oct 23. Cancer Treat Rev. 2015. PMID: 26508669 Review.
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S, Latorzeff I, Supiot S, Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fourneret P, Ruffion A, Dussart S. Carrie C, et al. Among authors: guerif s. Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160475 Clinical Trial.
[Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: experience of French dose-escalation trials].
Beckendorf V, Bachaud JM, Bey P, Bourdin S, Carrie C, Chapet O, Cowen D, Guérif S, Hay HM, Lagrange JL, Maingon P, Le Prisé E, Pommier P, Simon JM. Beckendorf V, et al. Among authors: guerif s. Cancer Radiother. 2002 Nov;6 Suppl 1:78s-92s. doi: 10.1016/s1278-3218(02)00217-2. Cancer Radiother. 2002. PMID: 12587386 Review. French.
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.
Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P. Belkacemi Y, et al. Among authors: guerif s. Cancer Radiother. 2020 Dec;24(8):892-897. doi: 10.1016/j.canrad.2020.03.014. Epub 2020 Nov 2. Cancer Radiother. 2020. PMID: 33144063 Review.
Reoxygenation during radiotherapy in intermediate-risk prostate cancer.
Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Supiot S, et al. Among authors: guerif s. Radiother Oncol. 2019 Apr;133:16-19. doi: 10.1016/j.radonc.2018.12.022. Epub 2019 Jan 12. Radiother Oncol. 2019. PMID: 30935573
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Carrie C, et al. Among authors: guerif s. Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16. Lancet Oncol. 2019. PMID: 31629656 Clinical Trial.
47 results